Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

1(25%)

Results Posted

200%(2 trials)

Terminated

2(50%)

Phase Distribution

Ph not_applicable

50%

Ph early_phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Active, not recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 11 (33.3%)

N/A2 (66.7%)

Trials by Status

active_not_recruiting125%

terminated250%

completed125%

Recent Activity

1 active trials

Showing 4 of 4

terminatednot_applicable

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

NCT01048853

active_not_recruitingnot_applicable

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

NCT02760849

completed

A Case Report of NMDAR Encephalopathy

NCT06915103

terminatedearly_phase_1

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

NCT03382574

Clinical Trials (4)

Showing 4 of 4 trials

NCT01048853Not Applicable

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

Terminated

NCT02760849Not Applicable

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Active Not Recruiting

NCT06915103

A Case Report of NMDAR Encephalopathy

Completed

NCT03382574Early Phase 1

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Terminated

All 4 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 4